ISSCR: grave omission of age limit for embryo research
By Josephine Johnston, Françoise Baylis, & Henry T. Greely,
Nature
| 06. 22. 2021
We are researchers with differing views on the ethics of stem-cell and embryo research who nonetheless share deep concerns about the latest guidelines from the International Society for Stem Cell Research (ISSCR; see R. Lovell-Badge Nature 593, 479; 2021).
The 2016 ISSCR guidelines ruled out experiments on human embryos beyond 14 days, citing broad international consensus that these lacked “a compelling scientific rationale, raise substantial ethical concerns, and/or are illegal in many jurisdictions” (see go.nature.com/3cqc4bw). The latest guidelines drop this prohibition (see go.nature.com/3gfkkw8) and do not propose any alternative.
At some point, the developing human embryo reaches a stage at which it should not be used for research. There is disagreement about when that happens, but scientists need to acknowledge that it does, and reassure the public that they accept limits. The latest guidelines do not prohibit the development or research use of ex vivo embryos at any stage.
Defining and defending a new limit, and possible constraints within it, will be hard. This was the case for the 14-day cut-off, selected some 40 years...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...